Eli Lilly and Company $LLY Shares Sold by WealthPLAN Partners LLC

WealthPLAN Partners LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 64.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 800 shares of the company’s stock after selling 1,429 shares during the period. WealthPLAN Partners LLC’s holdings in Eli Lilly and Company were worth $736,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. M.E. Allison & CO. Inc. raised its stake in shares of Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after buying an additional 10 shares in the last quarter. Tanager Wealth Management LLP boosted its stake in shares of Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after buying an additional 10 shares in the last quarter. Morey & Quinn Wealth Partners LLC grew its holdings in Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after acquiring an additional 10 shares during the period. Wealthspan Partners LLC grew its holdings in Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after acquiring an additional 10 shares during the period. Finally, G&S Capital LLC raised its position in Eli Lilly and Company by 2.0% in the fourth quarter. G&S Capital LLC now owns 501 shares of the company’s stock worth $538,000 after acquiring an additional 10 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 2.8%

NYSE:LLY opened at $1,233.32 on Wednesday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a fifty day simple moving average of $1,078.08 and a 200-day simple moving average of $1,030.27. The company has a market capitalization of $1.16 trillion, a PE ratio of 43.81, a price-to-earnings-growth ratio of 1.49 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 35.74 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan raised its price target on Eli Lilly to $1,400 from $1,300 and reiterated an overweight rating, signaling continued upside expectations for the stock. Benzinga report on JPMorgan price target raise
• Positive Sentiment: Shares hit a fresh 52-week high, reflecting momentum buying and strong investor enthusiasm around Lilly’s GLP-1 and obesity-treatment pipeline. CNBC report on Eli Lilly hitting 52-week high
• Positive Sentiment: Weak results from Kailera Therapeutics’ weight-loss pill IPO appear to have indirectly helped Lilly by reinforcing the market’s confidence in Lilly’s lead position in obesity drugs. Yahoo Finance article on Kailera setback and Lilly market cap
• Positive Sentiment: Commentary from Jim Cramer and other market-watch pieces remained constructive on biotech and Lilly’s growth story, suggesting investors still see the company as a core winner in the GLP-1 boom. 247WallSt Cramer commentary on Eli Lilly
• Neutral Sentiment: Several articles highlighted Lilly as a top healthcare stock to own and as a long-term growth story, but these were mainly opinion pieces rather than new company-specific developments. Motley Fool article on Eli Lilly stock
• Neutral Sentiment: Recent partnership and China-related business updates show Lilly is still actively managing its broader pipeline and regional strategy, but they appear less important than the obesity franchise news for today’s move. Yahoo Finance article on R&D collaboration and China rights transfer
• Negative Sentiment: Some coverage continues to point to regulatory and pricing-policy risks for Lilly, which could weigh on sentiment over time even as the stock remains strong now. Yahoo Finance article on regulatory and pricing policy challenges

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on LLY shares. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, July 1st. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Friday, June 5th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,243.22.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.